PDSB
PDS Biotechnology Corp
$1.16
+12.61%
$57.5M
No data for this timeframe.
Vol
Market Cap$57.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders5 funds
Inst. Value$1.6M
Inst. Activity0 buys / 2 sells
Reddit Sentiment43° Neutral
SEC Reports5
Press Releases3
Recent Activity
May 13, 2026
SEC
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, dri
PRESS-RELEASE — Impact 5/10
May 13, 2026
earnings
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
<p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p>
May 1, 2026
SEC
PDS Biotechnology entered a $6M promissory note with YA II PN, LTD (10% interest, 12-month maturity) and issued a warran
8-K — Impact 6/10
Apr 27, 2026
SEC
PDS Biotechnology Corp filed an S-3/A shelf registration statement, authorizing the potential issuance of up to $200 mil
S-3/A — Impact 4/10
Jan 12, 2026
Insider
BEDU-ADDO FRANK sold 548,782 shares
President/CEO @ $0.00 ($0.00)
Jan 12, 2026
Insider
CONN GREGORY sold 150,000 shares
Chief Scientific Officer @ $0.00 ($0.00)
Jan 12, 2026
Insider
Shepard Kirk V. sold 300,000 shares
Chief Medical Officer @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
176,700 shares ($136.0K)
Price Targets
$7.50
+546.6% upside
Strong Buy
Current $1.16
Low $3.00
Median $4.50
High $15.00
3 analysts
$3.00
$15.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 15, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 25, 2025 | B. Riley Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.13 ▲ +12.6% | $-0.14 — $-0.12 | 40% YoY | 3 |
| Next Q | $-0.12 ▲ +16.7% | $-0.15 — $-0.10 | 39% YoY | 3 |
| Current FY | $-0.50 ▲ +9.1% | $-0.60 — $-0.44 | 33% YoY | 3 |
| Next FY | $-0.47 ▲ +13.0% | $-0.61 — $-0.39 | 6% YoY | 3 |
Latest Reports
NEUTRAL
PRESS-RELEASE
5/10
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, dri
May 13, 2026
BEARISH
8-K
6/10
PDS Biotechnology entered a $6M promissory note with YA II PN, LTD (10% interest, 12-month maturity) and issued a warran
May 1, 2026
BULLISH
Press
8/10
PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 78% objective respons
Apr 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.5M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $136.0K | TRIM |
| WELLS FARGO & COMPANY/MN | $4.1K | — |
| MORGAN STANLEY | $3.8K | TRIM |
| BANK OF AMERICA CORP | $791.00 | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jan 12, 2026 | BEDU-ADDO FRANK | A | $0.00 |
| Jan 12, 2026 | CONN GREGORY | A | $0.00 |
| Jan 12, 2026 | Shepard Kirk | A | $0.00 |
| Jan 12, 2026 | Boesgaard Lars | A | $0.00 |
| Jan 12, 2026 | Brown Spencer | A | $0.00 |
Reddit Sentiment
43°
Neutral
Bearish
Neutral
Bullish
5 institutional holders with $1.6M total value (2,138,925 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, WELLS. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,950,946 | $1.5M | 91.2% | ADD +29.2% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 176,700 | $136.0K | 8.3% | TRIM -35.9% |
| 3 | WELLS FARGO & COMPANY/MN | 5,329 | $4.1K | 0.2% | — |
| 4 | MORGAN STANLEY | 4,922 | $3.8K | 0.2% | TRIM -40.4% |
| 5 | BANK OF AMERICA CORP /DE/ | 1,028 | $791.00 | 0.0% | ADD +60.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 275,861 | 176,700 | -35.9% | $136.0K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 8,259 | 4,922 | -40.4% | $3.8K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 105,687 | 275,861 | +161.0% | $278.6K | 2025-Q3 |
| UBS Group AG | TRIM | 543,021 | 200,236 | -63.1% | $202.2K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 648 | 1,037 | +60.0% | $1.0K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 1,510,221 | 1,951,343 | +29.2% | $2.6M | 2025-Q2 |
| UBS Group AG | DOUBLED | 251,156 | 543,021 | +116.2% | $722.2K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 105,687 | — | $140.6K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 17,315 | 7,434 | -57.1% | $9.9K | 2025-Q2 |
| FMR LLC | TRIM | 2,778 | 1,025 | -63.1% | $1.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 26,954 | 648 | -97.6% | $861.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 50,058 | 251,156 | +401.7% | $298.9K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 235,215 | 69,100 | -70.6% | $82.2K | 2025-Q1 |
| FMR LLC | DOUBLED | 847 | 2,778 | +228.0% | $3.3K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 100,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 65,732 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 121,982 | 235,215 | +92.8% | $383.4K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 23,200 | 100,000 | +331.0% | $163.0K | 2024-Q4 |
| UBS Group AG | DOUBLED | 20,234 | 50,058 | +147.4% | $81.6K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 27,432 | 17,894 | -34.8% | $29.2K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 13,278 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | TRIM | 73,988 | 27,432 | -62.9% | $104.8K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 13,278 | — | $50.7K | 2024-Q3 |
11 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | BEDU-ADDO FRANK | President/CEO | A | 548,782 | $0.00 | $0.00 |
| Jan 12, 2026 | CONN GREGORY | Chief Scientific Officer | A | 150,000 | $0.00 | $0.00 |
| Jan 12, 2026 | Shepard Kirk V. | Chief Medical Officer | A | 300,000 | $0.00 | $0.00 |
| Jan 12, 2026 | Boesgaard Lars | Chief Financial Officer | A | 300,000 | $0.00 | $0.00 |
| Jan 12, 2026 | Brown Spencer D. | Senior VP, General Counsel | A | 300,000 | $0.00 | $0.00 |
| Jan 12, 2026 | Toutain Stephan | Chief Operating Officer | A | 300,000 | $0.00 | $0.00 |
| Jan 12, 2026 | Freitag Gregory Gene | Director | A | 54,876 | $0.00 | $0.00 |
| Jan 12, 2026 | Iliev Ilian | Director | A | 54,876 | $0.00 | $0.00 |
| Jan 12, 2026 | Ali-Jackson Kamil | Director | A | 54,876 | $0.00 | $0.00 |
| Jan 12, 2026 | BRAWLEY OTIS W | Director | A | 54,876 | $0.00 | $0.00 |
| Jan 12, 2026 | Glover Stephen C. | Director | A | 54,876 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 5.8/10.
NEUTRAL
PRESS-RELEASE
5/10
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/sh
May 13, 2026
BEARISH
8-K
6/10
PDS Biotechnology entered a $6M promissory note with YA II PN, LTD (10% interest, 12-month maturity)
May 1, 2026
NEUTRAL
S-3/A
4/10
PDS Biotechnology Corp filed an S-3/A shelf registration statement, authorizing the potential issuan
Apr 27, 2026
BULLISH
8-K
6/10
PDS Biotechnology updated its corporate presentation deck, which includes positive clinical trial da
Apr 24, 2026
BULLISH
8-K
8/10
PDS Biotechnology announced positive interim Phase 2 clinical trial data for its drug PDS01ADC in tr
Apr 15, 2026
BULLISH
8/10
PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 7
Apr 15, 2026
MIXED
6/10
PDS Biotechnology reported financial results for 2025 and provided a clinical update, including a Ph
Mar 30, 2026
NEUTRAL
3/10
PDS Biotechnology announced it will report its Q4 and full-year 2025 financial results and provide a
Mar 24, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.50 mean target
+546.6% upside
Strong Buy (1.00)
$3.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $1.16 |
| Target Low | $3.00 |
| Target Mean | $7.50 |
| Target Median | $4.50 |
| Target High | $15.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.13 | $-0.14 | $-0.12 | 39.7% | +12.6% | — | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.12 | $-0.15 | $-0.10 | 38.6% | +16.7% | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.50 | $-0.60 | $-0.44 | 32.9% | +9.1% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-0.47 | $-0.61 | $-0.39 | 6.0% | +13.0% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.127 | |
| 7d ago | $-0.145 | +0.018 |
| 30d ago | $-0.145 | +0.018 |
| 60d ago | $0.000 | -0.127 |
| 90d ago | $-0.180 | +0.053 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 25, 2025 | B. Riley Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
43°
Neutral
Bearish
Neutral
Bullish
3 mentions
0 bullish
1 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 8, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 8, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Feb 20, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Open Discussion on PDSB
▲ 1
💬 1
⚡ 0.5
May 13, 2026
earnings
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
<p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p>
May 13, 2026
earnings_calendar
PDSB Q1 2026 Earnings Scheduled — 2026-05-13
Apr 15, 2026
announcement
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
<p align="center"><em>78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR </em><em>2-year survival rate of &g
Apr 10, 2026
short_volume
Short Volume: PDSB — 67.0% short (0.4M / 0.6M)
Short: 416,782 | Exempt: 144 | TRF Vol: 621,963 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: PDSB — 64.9% short (0.6M / 1.0M)
Short: 647,576 | Exempt: 12,735 | TRF Vol: 998,461 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
short_volume
Short Volume: PDSB — 68.6% short (0.4M / 0.5M)
Short: 356,718 | Exempt: 0 | TRF Vol: 519,959 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
<p align="center"><em>Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs</em></p
Mar 30, 2026
earnings_calendar
PDSB Q4 2025 Earnings After Market Close — 2026-03-30
Mar 26, 2026
earnings_calendar
PDSB Q4 2025 Earnings After Market Close — 2026-03-26
Mar 24, 2026
earnings
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
<p align="justify">PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”)